<DOC>
	<DOC>NCT02903498</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and tolerability of the maintenance treatment of tegafur-uracil (UFT) after the standard first-line chemotherapy in advanced gastric cancer.</brief_summary>
	<brief_title>The Maintenance Treatment of UFT in Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>Histologically confirmed advanced or metastatic adenocarcinoma of the stomach ECOG PS 02 At least one measurable or evaluable lesion in the firstline chemotherapy (5FU based regimen: ECF/EOF/EOX/FOLFOX/XELOX) with the efficacy evaluation of nonPD Adequate hepatic,renal,heart, and hematologic functions (platelets ≥75×109/L, neutrophil≥1.5×109/L, hemoglobin≥80 g/L, serum creatinine ≤1.5mg/dl, total bilirubin ≤1.5mg/dl, and serum transaminase≤2.5×the ULN) Receiving more or more than 2 regimens of chemotherapy Pregnant or lactating women Concurrent cancer History of other malignancies except cured basal cell carcinoma of skin and carcinoma insitu of uterine cervix Neuropathy, brain, or leptomeningeal involvement Clinically relevant coronary artery disease or a history of a myocardial infarction within the last 12 months or high risk/uncontrolled arrhythmia Uncontrolled significant comorbid conditions and previous radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>disease control survival</keyword>
</DOC>